IP Library › Granted Patent US 12,746,408
Granted Patent B2
US 12,746,408 · App. 18/546,214 · Granted Sep 29, 2026

Non-invasive cancer treatment

Inventors: José María Estrela Arigüel (Valencia, ES); José Juan Herrera Gaspar (Valencia, ES); Rosa María Cibrian Ortiz De Anda (Valencia, ES); Enrique Navarro Camba (Valencia, ES); María Elena Obrador Pla (Valencia, ES)
Assignees: SCIENTIA BIOTECH S.L; UNIVERSITAT DE VALENCIA
A61N2/002A61F7/02A61N2/004A61N2/02A61N7/02A61F2007/0054A61F2007/0282A61N2007/0004
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,746,408
App. No.
18/546,214
Granted
Sep 29, 2026
Kind
B2
Abstract

An apparatus ( 1 ) for treating a cancerous target site is provided. The apparatus comprises an electromagnetic emitter ( 10 ) comprising one or more electrodes with an electrically insulating coating for preventing electrical contact between the electrodes and the target site. The electromagnetic emitter ( 10 ) is configured to provide a tumour treating field at a target site ( 30 ) via the one or more electrodes, the tumour treating field being non-ionizing alternating electromagnetic field having a frequency of between 10 kHz to 300 kHz; and further having a magnetic flux density of between 0.1 pT and 1 mT. The apparatus further comprises a heat source ( 20 ) configured to provide heating at the target site to cause hyperthermia at the target site. The apparatus is configured to apply the non-ionizing alternating electromagnetic field and the heating independently. The apparatus comprises an electronic controller for electronically controlling the electromagnetic emitter and the heat source.

Claims (20)

1 . An apparatus for treating a cancerous target site, comprising:

an electromagnetic emitter comprising one or more electrodes with an electrically insulating coating for preventing electrical contact between the electrodes and the target site, the electromagnetic emitter configured to provide a tumour treating field at a target site via the one or more electrodes, the tumour treating field being a non-ionizing alternating electromagnetic field having a frequency of between 10 kHz to 300 kHz; and further having a magnetic flux density of between 0.1 pT and 1 mT;

a heat source configured to provide heating at the target site to cause hyperthermia at the target site; and

an electronic controller for electronically controlling the electromagnetic emitter and the heat source;

wherein the apparatus is configured to apply the non-ionizing alternating electromagnetic field and the heating independently.

2 . The apparatus of claim 1 , wherein the apparatus is configured to provide the non-ionizing alternating electromagnetic field at the target for a first time period, and to provide the heating at the target site for a second time period.

3 . The apparatus of claim 1 , wherein the apparatus is configured to provide the non-ionizing alternating electromagnetic field at the target site for a first time period of between 1 minute and 24 hours.

4 . The apparatus of claim 1 , wherein the apparatus is further configured to provide the heating at the target site for a second time period of between 1 minute and 360 minutes.

5 . The apparatus of claim 1 , wherein the electromagnetic emitter is configured to provide an alternating electromagnetic field at the target site having a magnetic flux density of between 0.1 pT and 100 μT.

6 . The apparatus according to claim 1 , wherein the electromagnetic emitter is configured to provide an alternating electromagnetic field at the target site having a magnetic flux density of between 0.5 μT and 1 mT.

7 . The apparatus according to claim 1 , wherein the electromagnetic emitter is configured to provide an alternating electromagnetic field at the target site having a magnetic flux density of between 8 μT and 1 mT.

8 . The apparatus of claim 1 , wherein electromagnetic emitter is configured to provide an alternating electromagnetic field having a frequency of between 100 kHz to 300 kHz.

9 . The apparatus of claim 1 , wherein the heat source is configured to heat the target site to a temperature of above 42° C. and preferably between 42° C. and 57° C.

10 . The apparatus of claim 1 , wherein the heat source comprises an ultrasonic emitter configured to provide ultrasound radiation to the target site.

11 . The apparatus of claim 1 , wherein the heat source comprises an electromagnetic emitter configured to provide electromagnetic radiation to the target site.

12 . The apparatus of claim 1 , wherein the heat source comprises a fluidic pump configured to pump fluid to the target site and a heater to heat the fluid before it reaches the target site.

13 . The apparatus of claim 1 , wherein the heat source comprises a conductive heat emitter configured to provide heat to the target site by conduction of heat.

14 . The apparatus of claim 4 , wherein the heating is applied simultaneously to the non-ionizing alternating electromagnetic field for a third time period.

15 . The apparatus of claim 9 , wherein the heat source is configured to heat the target site to a temperature of between 42° C. and 57° C.

16 . The apparatus of claim 10 , wherein the ultrasound radiation has one or more focal areas in the target site.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2026
From: HERRERA GASPAR, JOSÉ JUAN
To: SCIENTIA BIOTECH S.L
Reel/Frame 075795/0034 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2026
From: ESTRELA ARIGÜEL, JOSÉ MARÍA; CIBRIAN ORTIZ DE ANDA, ROSA MARÍA; NAVARRO CAMBA, ENRIQUE; OBRADOR PLA, MARÍA ELENA
To: UNIVERSITAT DE VALÈNCIA
Reel/Frame 074789/0919 →
Priority Claims (1)
EP 21382115 · Feb 12, 2021 · regional
Continuity (1)
Related Publication 20240131352A1 · Apr 25, 2024
References Cited (47)
US 4934365A · Morgenthaler · 1990 [cited by applicant]
US 5183456A · Liboff · 1993 [cited by examiner]
US 5734033A · Reed · 1998 [cited by applicant]
US 5831066A · Reed · 1998 [cited by applicant]
US 6565887B1 · Gray et al. · 2003 [cited by applicant]
US 6640139B1 · Ueberle · 2003 [cited by applicant]
US 7410469B1 · Talish · 2008 [cited by examiner]
US 10881882B1 · Schwarz et al. · 2021 [cited by applicant]
US 20040199070A1 · Krockel · 2004 [cited by applicant]
US 20110306870A1 · Kuhn · 2011 [cited by applicant]
US 20120253099A1 · Mon et al. · 2012 [cited by applicant]
US 20130053620A1 · Susedik et al. · 2013 [cited by applicant]
US 20130238061A1 · Ron Edoute et al. · 2013 [cited by applicant]
US 20140276743A1 · Curley · 2014 [cited by applicant]
US 20170014637A1 · Basser · 2017 [cited by applicant]
US 20170165003A1 · Schoenbach et al. · 2017 [cited by applicant]
US 20180001105A1 · Botsford · 2018 [cited by examiner]
US 20200107882A1 · Townley et al. · 2020 [cited by applicant]
US 20200246179A1 · Peyman · 2020 [cited by applicant]
US 20200254272A1 · Sharma · 2020 [cited by applicant]
US 20200306554A1 · Ron Edoute et al. · 2020 [cited by applicant]
US 20210401288A1 · Weil · 2021 [cited by examiner]
CA 2738073C · 2016 [cited by examiner]
CN 102488967A · 2012 [cited by applicant]
CN 103272332A · 2013 [cited by examiner]
CN 106794354A · 2017 [cited by applicant]
CN 109475735A · 2019 [cited by applicant]
CN 111481823A · 2020 [cited by applicant]
WO WO9837907A1 · 1998 [cited by applicant]
WO WO0156656A1 · 2001 [cited by examiner]
WO WO03040182A1 · 2003 [cited by applicant]
WO WO2020141527A1 · 2020 [cited by applicant]
Estrela et al., “Elimination of Ehrlich tumours by ATP-induced growth inhibition, glutathione depletion and X-rays,” [cited by applicant]
Gumireddy et al., “NOV-002, A Glutathione Disulfide Mimetic, Suppresses Tumor Cell Invasion and Metastasis,” [cited by applicant]
Kawamura et al., “A small molecule that induces reactive oxygen species via cellular glutathione depletion,” [cited by applicant]
McBean et al., “Molecular mechanisms of cystine transport,” [cited by applicant]
Mena et al., “Bcl-2 and Glutathione Depletion Sensitizes B16 Melanoma to Combination Therapy and Eliminates Metastatic Disease,” [cited by applicant]
Min et al., “Glucocorticoid receptor antagonist sensitizes TRAIL-induced apoptosis in renal carcinoma cells through up-regulation of DR5 and down-regulation of c-FLIP(L) and Bcl-2,” [cited by applicant]
Obrador et al., “γ-Glutamyl Transpeptidase Overexpression Increases Metastatic Growth of B16 Melanoma Cells in the Mouse Liver,” [cited by applicant]
Obrador et al., “Intertissue Flow of Glutathione (GSH) as a Tumor Growth-promoting Mechanism,” [cited by applicant]
Olson et al., “Detection of MRP Functional Activity: Calcein AM but not BCECF AM as a Multidrug Resistance-Related Protein (MRP1) Substrate,” [cited by applicant]
Ortega et al., “Glutathione in Cancer Cell Death,” [cited by applicant]
Pei et al., “Targeting Aberrant Glutathione Metabolism to Eradicate Human Acute Myelogenous Leukemia Cells,” [cited by applicant]
Shao et al., “BET Protein Inhibitor JQ1 Attenuates Myc-Amplified MCC Tumor Growth In Vivo,” [cited by applicant]
Silber et al., “Adaptation of γ-Glutamyl Transpeptidase Assay to Microtiter Plates,” [cited by applicant]
Terradez et al., “Depletion of tumour glutathione in vivo by buthionine sulphoximine: modulation by the rate of cellular proliferation and inhibition of cancer growth,” [cited by applicant]
Trachootham et al., “Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanate,” [cited by applicant]